Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer
Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer
Not yet recruiting · NCT07793578 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer | Advanced Urothelial Carcinoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT07793578 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| VA Office of Research and Development | 472 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA | Philadelphia | United States | 25 |
| VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA | Boston | United States | 34 |
| VA Connecticut Healthcare System West Haven Campus, West Haven, CT | West Haven | United States | 25 |
| VA Puget Sound Health Care System Seattle Division, Seattle, WA | Seattle | United States | 32 |